Quantcast

Latest Cladribine Stories

2011-06-28 00:00:33

This report provides perspective on the MS landscape in light of Merck Serono's decision to discontinue development and marketing of cladribine for MS. Scottsdale, AZ (PRWEB) June 27, 2011 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled "Thought Leader Insight & Analysis: Multiple Sclerosis," designed to provide critical strategic insight for pharma and biotech companies with a stake in the...

2011-03-02 01:25:00

ROCKLAND, Mass., March 2, 2011 - EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS). (Logo: http://photos.prnewswire.com/prnh/20101126/SF07905LOGO-b) A complete response...

2010-12-15 07:00:00

BURLINGTON, Mass., Dec. 15, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed neurologists in the EU5--France, Germany, Italy, Spain and the United Kingdom--expect that both Novartis/Mitsubishi Tanabe's oral agent Gilenya (FTY-720/fingolimod) and Merck Serono's oral cladribine will most likely secure initial European approval for use in relapsing forms of multiple...

2010-11-26 01:18:00

ROCKLAND, Mass., Nov. 26, 2010 /PRNewswire/ -- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S. Food and Drug Administration (FDA) has extended its review period for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS) by three months to February 28, 2011. The FDA granted Priority Review status for Cladribine Tablets in July of 2010, reducing the standard 10-month review period to six months, which was set to end on...

2010-08-04 13:30:00

WALTHAM, Mass., Aug. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 83 percent of surveyed physicians are familiar with Merck Serono/EMD Serono's oral cladribine and Novartis/Mitsubishi Tanabe's FTY-720/fingolimod/Gilenia (when all three names are surveyed) among the surveyed oral emerging therapies for the treatment of multiple sclerosis (MS). Updated data from a survey fielded in July...

2010-07-28 02:38:00

ROCKLAND, Mass., July 28 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS). The application also has been granted a Priority Review designation by the FDA, which means the review period for the NDA is reduced. The goal for completing a Priority Review is six...

2010-07-12 07:00:00

WALTHAM, Mass., July 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of several high-priced novel disease-modifying therapies--including the first oral agents approved for the indication--will fuel modest 3 percent annual growth in the multiple sclerosis (MS) drug market through 2019, coupled with increasing use of current and emerging monoclonal antibodies. The Pharmacor 2010...

2010-01-21 00:30:00

ROCKLAND, Mass., Jan. 21 /PRNewswire/ -- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY(1) Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine(2). The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with...

2010-01-20 18:20:54

A new drug for multiple sclerosis promises to change the lives of the 100,000 people in the UK who have the condition, say researchers at Queen Mary, University of London. A major trial of the oral drug Cladribine "“ results of which are published in the New England Journal of Medicine on 20 January 2010 "“ has shown that it significantly reduces relapse and deterioration of the disease, and goes a long way to eliminating the unpleasant side effects associated with existing...

2010-01-06 07:30:00

CAMBRIDGE, Mass., Jan. 6 /PRNewswire/ -- Sermo (http://www.sermo.com), the world's largest online physician's community, today announced a new Sermo Event(TM) Report assessing physician perception of FDA's "refuse to file" (RTF) letter on EMD Serono's Cladribine tablets and its potential impact, if any, on Novartis' oral MS agent in development; Fingolimod. Cladribine is expected to be one of the first oral agents to be approved for the treatment of relapsing and remitting multiple...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related